Repligen Co. (NASDAQ:RGEN) Receives $301.50 Average Price Target from Analysts

Repligen Co. (NASDAQ:RGENGet Rating) has been given a consensus recommendation of “Moderate Buy” by the seven research firms that are presently covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a hold rating and five have issued a buy rating on the company. The average 12 month price target among brokers that have issued ratings on the stock in the last year is $301.50.

A number of equities research analysts have recently commented on RGEN shares. Craig Hallum cut their price objective on Repligen from $286.00 to $274.00 in a research report on Thursday, April 28th. StockNews.com started coverage on Repligen in a research report on Thursday, March 31st. They set a “hold” rating for the company.

In other news, Director Karen A. Dawes sold 14,715 shares of the stock in a transaction on Wednesday, May 25th. The stock was sold at an average price of $150.51, for a total value of $2,214,754.65. Following the completion of the sale, the director now owns 76,532 shares in the company, valued at $11,518,831.32. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 1.10% of the stock is owned by corporate insiders.

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. First Trust Advisors LP increased its stake in shares of Repligen by 174.3% in the fourth quarter. First Trust Advisors LP now owns 135,124 shares of the biotechnology company’s stock worth $35,786,000 after acquiring an additional 85,857 shares during the last quarter. Cambridge Investment Research Advisors Inc. increased its stake in shares of Repligen by 24.9% in the fourth quarter. Cambridge Investment Research Advisors Inc. now owns 5,480 shares of the biotechnology company’s stock worth $1,451,000 after acquiring an additional 1,094 shares during the last quarter. Schonfeld Strategic Advisors LLC acquired a new position in shares of Repligen in the third quarter worth $816,000. National Asset Management Inc. increased its stake in shares of Repligen by 16.0% in the fourth quarter. National Asset Management Inc. now owns 1,865 shares of the biotechnology company’s stock worth $494,000 after acquiring an additional 257 shares during the last quarter. Finally, Kenfarb & CO. acquired a new position in shares of Repligen in the fourth quarter worth $185,000. Institutional investors own 86.82% of the company’s stock.

Shares of NASDAQ:RGEN opened at $148.71 on Thursday. Repligen has a one year low of $137.21 and a one year high of $327.32. The stock has a fifty day moving average of $154.74 and a 200-day moving average of $186.68. The company has a market capitalization of $8.09 billion, a PE ratio of 58.78 and a beta of 0.98.

Repligen (NASDAQ:RGENGet Rating) last announced its quarterly earnings data on Wednesday, April 27th. The biotechnology company reported $0.92 EPS for the quarter, beating analysts’ consensus estimates of $0.72 by $0.20. Repligen had a return on equity of 11.13% and a net margin of 19.86%. The company had revenue of $206.40 million during the quarter, compared to the consensus estimate of $185.48 million. During the same quarter in the prior year, the firm earned $0.68 EPS. The company’s quarterly revenue was up 44.5% compared to the same quarter last year. As a group, research analysts expect that Repligen will post 3.1 earnings per share for the current fiscal year.

Repligen Company Profile (Get Rating)

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.

See Also

Analyst Recommendations for Repligen (NASDAQ:RGEN)

Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.